With its lead project tipifarnib looking pretty elderly, Kura Oncology will have been relieved with data presented at Ash on Saturday suggesting that its oral menin inhibitor KO-539 has potential in acute myeloid leukaemia. The phase I Komet-001 study enrolled 12 patients with advanced AML who had received a median three prior therapies. The Ash dataset covered eight of these patients, two of whom had complete response. These occurred in NPM1-mutant patients, suggesting this as another biomarker-based treatment in AML; a third NPM1 mutant was not evaluable for efficacy at the data cut. Kura expects to find a phase II dose in the first quarter of 2021, at which point it will expand into cohorts in NPM1-mutant patients and those with KMT2A/MLL rearrangements, the populations in which Kura believes KO‑539 could show “pronounced clinical benefit”. NPM1 mutations occur in around 30% of people with AML. The only other menin inhibitor in clinical development is Syndax Pharmaceuticals’ SNDX-5613: this has higher consensus sales forecasts than KO-539, but given the Ash data this situation might change. As for Kura itself, its stock was up 5% this morning.